相关实验视频
Updated: Jun 11, 2025

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
在Fontan息治疗后的胰岛素耐药性
Erin V Shea1, Sunkyung Yu2, Kurt R Schumacher2
1Pediatric Cardiology, Duke University Medical Center, Durham, NC, USA.
接受芬坦息治疗 (S/P Fontan) 的患者具有更高的胰岛素抵抗 (IR). 这种IR随着年龄的增长而增加,并且与长期的心脏风险有关,因此需要在S/P Fontan个体中早期检测.
科学领域:
- 心脏病学 心脏病学
- 代谢健康 代谢健康
- 儿科健康 儿科健康
背景情况:
- 在Fontan息后 (S/P Fontan) 患有单心室心脏生理病的患者面临获得性发病的风险增加.
- 胰岛素耐药性 (IR) 是众所周知的心脏病发病率和死亡率的预测因子.
研究的目的:
- 评估和比较患者的胰岛素抵抗 (IR) S/P Fontan与健康对照.
- 调查S/P Fontan队列中年龄和IR之间的关联.
主要方法:
- 一个单中心的横截面研究包括59名S/P Fontan患者和30名对照.
- 使用定量胰岛素指数 (QUICKI) 和ln (HOMA-IR) 评估胰岛素耐药性.
- 进行了与年龄调整或不调整的分析,并排除了肥胖患者.
主要成果:
- 与对照组相比,S/P Fontan患者的QUICKI显著降低,ln (HOMA-IR) 较高 (p < 0.0001),即使经过年龄调整.
- 红外线患病率在S/P Fontan患者 (69.5%通过QUICKI,54.2%通过HOMA-IR) 与对照组相比 (分别为10%和16.7%) 显著更高.
- 在S/P Fontan组中,随着年龄的增长,IR的显著逐渐增加被观察到.
结论:
- 与对照组相比,S/P Fontan患者表现出明显更高的胰岛素抵抗.
- 在S/P Fontan人口中,IR的患病率随着年龄的增长而增加.
- 在S/P Fontan患者中早期发现和治疗IR至关重要,因为它与长期发病率和死亡率有关.
更多相关视频
08:22Combined Intravital Microscopy and Contrast-enhanced Ultrasonography of the Mouse Hindlimb to Study Insulin-induced Vasodilation and Muscle Perfusion
Published on: March 20, 2017
06:27Wireless Telemetry Device Implantation in a Fontan Ovine Model for Continuous and Long-Term Hemodynamic Monitoring
Published on: May 2, 2025
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Diabetes Mellitus: Type 2 and Gestational
Oral Hypoglycemic Agents: Biguanides and Glitazones
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Dipeptidyl Peptidase 4 Inhibitors